Palvella Therapeutics, Inc. (PVLA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Palvella Therapeutics, Inc. (PVLA) closed at USD 122.58 on 2026-10-14, a change of +66.8 % over the past year, with a market capitalization of USD 1.83B.

Palvella Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Palvella Therapeutics, Inc. key figures

Previous close

USD 122.58 (2026-10-14)

1-year change

+66.8 %

Market cap

USD 1.83B

Enterprise value

USD 1.61B

P/E ratio (trailing)

-26.53

P/E ratio (forward)

-15.71

EPS (trailing)

-4.80

EPS (forward)

-8.11

PEG ratio

n/a

Price to book

8.45

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.77

Employees

29

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Palvella Therapeutics, Inc. and compare it with other stocks.